Trial Details
Liso-cel + Chemotherapy
Recruiting
Area of Research: FL/MZL: 2L+/ 3L+
Phase 2

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Brief Summary:

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL.The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.This study is divided into three periods:Pretreatment, which consists of screening assessments, leukapheresis and the Pretreatment evaluation; Treatment, which starts with the administration of lymphodepleting (LD) chemotherapy and continues through JCAR017 administration at Day 1 with follow-up through Day 29; Posttreatment, which includes follow-up assessments for disease status and safety for 2 years.

For more information, please contact the recruiting sites directly.
If there is no contact information, please email: Clinical.Trials@bms.com. The first line of the email MUST contain the NCT # and Site #.

38 locations available.
close-icon

Log In

Log in below to access your account on BMS Science or Bolder Science. If you have an existing Bolder Science account, please use your login credentials for that account here.

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create Account

Use the form below to create one account that will be used across both BMS Science and Bolder Science. Clinical trials that you save on either site will be shown together on your dashboard on Bolder Science. If you already have an account, you can log in here.

  • 8 characters minimum
  • First character cannot be a number
  • Last character cannot be a number